Literature DB >> 16786357

The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma.

Hui Zhang1, Qing-Hai Ye, Ning Ren, Lei Zhao, Yan-Fang Wang, Xin Wu, Hui-Chuan Sun, Lu Wang, Bo-Heng Zhang, Yin-Kun Liu, Zhao-You Tang, Lun-Xiu Qin.   

Abstract

We aimed to evaluate the prognostic value of preoperative plasma osteopontin (OPN) levels in 101 patients with hepatocellular carcinoma (HCC) who underwent liver resection. Plasma OPN levels were detected by ELISA. The association of plasma OPN levels of patients with clinicopathological characteristics, tumor recurrence, and survival was analyzed. The median plasma OPN level of patients was 176.90 ng/ml (range 13.73-780.00 ng/ml), which was significantly higher than that of 24 healthy volunteers (63.74 ng/ml, range 12.20-122.32 ng/ml). Plasma OPN levels were significantly different in patients with different numbers of tumor nodules (168.18 and 217.11 ng/ml for single and multiple nodules, respectively; P = 0.002), different Edmondson's grades (201.24, 168.36, and 503.58 ng/ml for grades I, II, and III/IV, respectively; P = 0.015), and different TNM stages (168.16, 167.54, and 216.18 ng/ml for stages I, II, and III/IV, respectively; P = 0.016). Significantly higher plasma OPN levels were found in patients with a recurrence of HCC after resection, compared with those without recurrence (213.55 versus 153.70 ng/ml; P = 0.0013). A higher plasma OPN level was a leading independent prognostic factor for both overall survival (OS) and disease-free survival (DFS) in univariate and multivariate Cox models. This suggests that the preoperative plasma OPN level can be used as a predictive marker for HCC recurrence and may be helpful to assess the prognosis of patients with HCC after surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786357     DOI: 10.1007/s00432-006-0119-3

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  51 in total

1.  Co-expression of osteopontin and CD44v9 in gastric cancer.

Authors:  T Ue; H Yokozaki; Y Kitadai; S Yamamoto; W Yasui; T Ishikawa; E Tahara
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

2.  Molecular staging for survival prediction of colorectal cancer patients.

Authors:  Steven Eschrich; Ivana Yang; Greg Bloom; Ka Yin Kwong; David Boulware; Alan Cantor; Domenico Coppola; Mogens Kruhøffer; Lauri Aaltonen; Torben F Orntoft; John Quackenbush; Timothy J Yeatman
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

3.  The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

4.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

5.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

6.  Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line.

Authors:  H Chen; Y Ke; A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1997-04-03       Impact factor: 9.867

Review 7.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

8.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

9.  Predictors and patterns of recurrence after resection of hepatocellular carcinoma.

Authors:  Charles Cha; Yuman Fong; William R Jarnagin; Leslie H Blumgart; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

10.  Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.

Authors:  Gabriele Carlinfante; Daphne Vassiliou; Olle Svensson; Mikael Wendel; Dick Heinegård; Göran Andersson
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more
  33 in total

1.  Identification of osteopontin as a novel marker for early hepatocellular carcinoma.

Authors:  Sufen Shang; Amelie Plymoth; Shaokui Ge; Ziding Feng; Hugo R Rosen; Suleeporn Sangrajrang; Pierre Hainaut; Jorge A Marrero; Laura Beretta
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

2.  Association of circulating osteopontin levels with clinical outcomes in postoperative biliary atresia.

Authors:  Sittisak Honsawek; Paisarn Vejchapipat; Voranush Chongsrisawat; Nutchanart Thawornsuk; Yong Poovorawan
Journal:  Pediatr Surg Int       Date:  2010-11-03       Impact factor: 1.827

3.  Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.

Authors:  Holger G Hass; Oliver Nehls; Juergen Jobst; Andrea Frilling; Ulrich Vogel; Stephan Kaiser
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

4.  Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression.

Authors:  Ermira Pazolli; Elise Alspach; Agnieszka Milczarek; Julie Prior; David Piwnica-Worms; Sheila A Stewart
Journal:  Cancer Res       Date:  2012-03-15       Impact factor: 12.701

5.  Significance of plasma osteopontin levels in patients with bladder urothelial carcinomas.

Authors:  Li Zhao; Yalin Wang; Nan Qu; Chen Huang; Lijun Chen
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

6.  Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.

Authors:  Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Hellmuth-A Meyer; Stefan A Loening; Klaus Jung
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

7.  Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.

Authors:  Justin D Blasberg; Harvey I Pass; Chandra M Goparaju; Raja M Flores; Suzie Lee; Jessica S Donington
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

Review 8.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

9.  Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH.

Authors:  Jin-Cai Wu; Bing-Sheng Sun; Ning Ren; Qing-Hai Ye; Lun-Xiu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-16       Impact factor: 4.553

Review 10.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.